POLA-Hi-CHP+orelabrutinib
Phase 2
POLA-Hi-CHP+orelabrutinib is one of 8 therapeutic programs targeting DLBCL - Diffuse Large B Cell Lymphoma. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
7
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
13 competitors in DLBCL - Diffuse Large B Cell Lymphoma
#DrugCompanyPhaseTrials
1Gemzar
Johnson & JohnsonPhase 3
Eloxatin
TevaPhase 3
Jaypirca
Eli LillyPhase 2
Dexametasone
UUniversity of Malaya
Phase 3
R-CHOP
IIncyte Biosciences Japan GK
Phase 2
POLA-R-CHP
FFudan University
Phase 2
POLA-Hi-CHP+orelabrutinib
OOu Bai, MD/PHD
Phase 2
R-Minichop
UUniversität des Saarlandes
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for POLA-Hi-CHP+orelabrutinib. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 2[1]
- Company
- OOu Bai, MD/PHD